Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder

References

• Ohayon MM, Hong SC. Prevalence of major depressive disorder in the general population of South Korea. J Psychiatr Res 2006; 40: 30–6
   PubMed Web of Science ®Google Scholar
• Spaner D, Bland RC, Newman SC. Epidemiology of psychiatric disorders in Edmonton. Major depressive disorder. Acta Psychiatr Scand Suppl 1994; 376: 7–15
   PubMedGoogle Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003; 289: 3095–105
   PubMed Web of Science ®Google Scholar
• Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 2005; 62: 1097–106
   PubMed Web of Science ®Google Scholar
• Williams DR, Gonzalez HM, Neighbors H, Nesse R, Abelson JM, Sweetman J, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the National Survey of American Life. Arch Gen Psychiatry 2007; 64: 305–15
   PubMed Web of Science ®Google Scholar
• Rytsala HJ, Melartin TK, Leskela US, Sokero TP, Lestela-Mielonen PS, Isometsa ET. Predictors of long-term work disability in Major Depressive Disorder: a prospective study. Acta Psychiatr Scand 2007; 115: 206–13
   PubMed Web of Science ®Google Scholar
• Rytsala HJ, Melartin TK, Leskela US, Sokero TP, Lestela-Mielonen PS, Isometsa ET. Functional and work disability in major depressive disorder. J Nerv Ment Dis 2005; 193: 189–95
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M, et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry 2006; 67: 185–95
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 2004; 26: 13–7
   PubMed Web of Science ®Google Scholar
• Coryell W, Young E, Carroll B. Hyperactivity of the hypothalamic-pituitary-adrenal axis and mortality in major depressive disorder. Psychiatry Res 2006; 142: 99–104
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Birnbaum HG. The economic burden of depression in the US: societal and patient perspectives. Expert Opin Pharmacother 2005; 6: 369–76
   PubMed Web of Science ®Google Scholar
• Hu TW. The economic burden of depression and reimbursement policy in the Asia Pacific region. Australas Psychiatry 2004; 12(Suppl): S11–15
   PubMedGoogle Scholar
• Gadit AA. Economic burden of depression in Pakistan. J Pak Med Assoc 2004; 54: 43–4
   PubMedGoogle Scholar
• Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–18
   PubMed Web of Science ®Google Scholar
• Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer D. The economic burden of depression. Gen Hosp Psychiatry 1986; 8: 387–94
   PubMed Web of Science ®Google Scholar
• Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191–5
   PubMed Web of Science ®Google Scholar
• Sobocki P, Lekander I, Borgstrom F, Strom O, Runeson B. The economic burden of depression in Sweden from 1997 to 2005. Eur Psychiatry 2007; 22: 146–52
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003; 64: 1465–75
   PubMed Web of Science ®Google Scholar
• Luo H, Richardson JS. A pharmacological comparison of citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. Int Clin Psychopharmacol 1993; 8: 3–12
   PubMed Web of Science ®Google Scholar
• Ventura D, Armstrong EP, Skrepnek GH, Haim EM. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 2007; 23: 245–50
   PubMed Web of Science ®Google Scholar
• Wade A, Despiegel N, Heldbo RE. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry 2006; 18: 83–9
   PubMedGoogle Scholar
• Baldwin DS, Cooper JA, Huusom AK, Hindmarch I. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006; 21: 159–69
   PubMed Web of Science ®Google Scholar
• Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005; 21: 1659–68
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20: 131–7
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190–6
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57–64
   PubMed Web of Science ®Google Scholar
• Wade A, Gembert K, Florea I. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007; 23: 1605–14
   PubMed Web of Science ®Google Scholar
• Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 2007; 27: 481–92
   PubMed Web of Science ®Google Scholar
• Sorensen J, Stage KB, Damsbo N, Lay AL, Hemels ME. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007; 61: 100–8
   PubMed Web of Science ®Google Scholar
• Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007; 61: 702–10
   PubMed Web of Science ®Google Scholar
• Fantino B, Moore N, Verdoux H, Auray JP. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 2007; 22: 107–15
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005; 21: 631–42
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005; 27: 111–24
   PubMed Web of Science ®Google Scholar
• Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23: 155–67
   PubMed Web of Science ®Google Scholar
• Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4: 12–9
   PubMedGoogle Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004; 20: 869–78
   PubMed Web of Science ®Google Scholar
• Lothgren M, Hemels ME, Francois C, Jonsson B. A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Primary Care Psychiatry 2004; 9: 153–61
   Google Scholar
• Chiu E. Epidemiology of depression in the Asia Pacific region. Australas Psychiatry 2004; 12(Suppl): S4–10
   PubMedGoogle Scholar
• Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econom 2002; 5: 91–107
   Google Scholar
• Ministry of Health. Clinical Practice Guidelines–Depression. Singapore: Ministry of Health; 2004.
   Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–7
   PubMed Web of Science ®Google Scholar
• Haffmans PM, Timmerman L, Hoogduin CA. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol 1996; 11: 157–64
   PubMed Web of Science ®Google Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004; 19: 305–10
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21: 297–309
   PubMed Web of Science ®Google Scholar
• Lancon C, Verpillat P, Annemans L, Despiegel N, Francois C. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int J Psychiatry Clin Pract 2007; 11: 44–52
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001; 62: 135–42
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181–8
   PubMed Web of Science ®Google Scholar
• Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10(Suppl 1)29–35
   PubMedGoogle Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44–9
   PubMed Web of Science ®Google Scholar
• Kornstein SG, Bose A, Li D, Saikali KG, Gandhi C. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 1767–75
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry 2006; 163: 101–8
   PubMed Web of Science ®Google Scholar
• Drummond M. Cost-of-illness studies: a major headache?. Pharmacoeconomics 1992; 2: 1–4
   PubMedGoogle Scholar
• Department of Statistics. Yearbook of Statistics Singapore. Singapore: Department of Statistics, Ministry of Trade & Industry, Republic of Singapore; 2005.
   Google Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005; 27: 486–96
   PubMed Web of Science ®Google Scholar